You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/74961
Full metadata record
DC FieldValueLanguage
dc.contributor.authorButtros, Daniel de Araújo Brito-
dc.contributor.authorNahás, Eliana Aguiar Petri-
dc.contributor.authorVespoli, Heloísa Maria de Luca-
dc.contributor.authorUemura, Gilberto-
dc.contributor.authorDe Almeida, Bruno Da Rosa-
dc.contributor.authorNahas-Neto, Jorge-
dc.date.accessioned2014-05-27T11:28:46Z-
dc.date.accessioned2016-10-25T18:46:06Z-
dc.date.available2014-05-27T11:28:46Z-
dc.date.available2016-10-25T18:46:06Z-
dc.date.issued2013-04-01-
dc.identifierhttp://dx.doi.org/10.1097/GME.0b013e318272bd4a-
dc.identifier.citationMenopause, v. 20, n. 4, p. 448-454, 2013.-
dc.identifier.issn1072-3714-
dc.identifier.issn1530-0374-
dc.identifier.urihttp://hdl.handle.net/11449/74961-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/74961-
dc.description.abstractThe aim of this study was to assess the risk of metabolic syndrome (MetS) in postmenopausal breast cancer survivors as compared with postmenopausal women without breast cancer. METHODS: In this cross-sectional study, 104 postmenopausal breast cancer survivors were compared with 208 postmenopausal women (controls) attending a university hospital. Eligibility criteria included the following: amenorrhea longer than 12 months and aged 45 years or older, treated for breast cancer, and metastasis-free for at least 5 years. The control group consisted of women with amenorrhea longer than 12 months and aged 45 years or older and without breast cancer, matched by age and menopause status (in a proportion of 1:2 as sample calculation). Clinical and anthropometric data were collected. Biochemical parameters, including total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, glucose, and C-reactive protein, were measured. Women showing three or more diagnostic criteria were diagnosed as having MetS: waist circumference of 88 cm or larger, blood pressure of 130/85 mm Hg or higher, triglycerides level of 150 mg/dL or higher, high-density lipoprotein cholesterol level lower than 50 mg/dL, and glucose level of 100 mg/dL or higher. For statistical analysis, Student's t test, χ2 test, and logistic regression (odds ratio [OR]) were used. RESULTS: The mean (SD) age of breast cancer survivors was 60.6 (8.6) years, with a mean (SD) follow-up of 9.4 (4.4) years. A higher percentage of breast cancer survivors (46.2%) were obese as compared with controls (32.7%; P < 0.05), and a smaller percentage showed optimal values for low-density lipoprotein cholesterol, glucose, and C-reactive protein versus controls (P < 0.05). MetS was diagnosed in 50% of breast cancer survivors and in 37.5% of control group women (P < 0.05). Among the MetS diagnostic criteria, the most prevalent was abdominal obesity (waist circumference >88 cm), affecting 62.5% and 67.8% of the participants, respectively. In the control group, breast cancer survivors had a higher risk for MetS (OR, 1.66; 95% CI, 1.04-2.68), dysglycemia (OR, 1.05; 95% CI, 1.09-3.03), and hypertension (OR, 1.71; 95% CI, 1.02-2.89). CONCLUSIONS: Postmenopausal breast cancer survivors present a higher risk of developing MetS as compared with women without breast cancer. © 2012 by The North American Menopause Society.en
dc.format.extent448-454-
dc.language.isoeng-
dc.sourceScopus-
dc.subjectBreast cancer survivors-
dc.subjectMenopause-
dc.subjectMetabolic syndrome-
dc.subjectRisk factors-
dc.subjectC reactive protein-
dc.subjectcholesterol-
dc.subjectestrogen receptor-
dc.subjectglucose-
dc.subjecthigh density lipoprotein cholesterol-
dc.subjectlow density lipoprotein cholesterol-
dc.subjectprogesterone receptor-
dc.subjecttriacylglycerol-
dc.subjectabdominal obesity-
dc.subjectadult-
dc.subjectamenorrhea-
dc.subjectarterial pressure-
dc.subjectaxillary lymph node-
dc.subjectblood pressure-
dc.subjectbody mass-
dc.subjectbreast cancer-
dc.subjectcancer chemotherapy-
dc.subjectcancer hormone therapy-
dc.subjectcancer radiotherapy-
dc.subjectcancer size-
dc.subjectcancer survivor-
dc.subjectcardiometabolic risk-
dc.subjectcholesterol blood level-
dc.subjectconservative treatment-
dc.subjectcontrolled study-
dc.subjectcross-sectional study-
dc.subjectdisease duration-
dc.subjectdisease severity-
dc.subjectexercise-
dc.subjectfemale-
dc.subjectfollow up-
dc.subjectglucose blood level-
dc.subjecthormone substitution-
dc.subjecthuman-
dc.subjecthypertension-
dc.subjectmajor clinical study-
dc.subjectmastectomy-
dc.subjectmetabolic syndrome X-
dc.subjectparity-
dc.subjectpostmenopause-
dc.subjectprotein blood level-
dc.subjectrisk assessment-
dc.subjecttriacylglycerol blood level-
dc.subjectwaist circumference-
dc.titleRisk of metabolic syndrome in postmenopausal breast cancer survivorsen
dc.typeoutro-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.description.affiliationDepartment of Gynecology and Obstetrics Botucatu Medical School Sao Paulo State University, São Paulo-
dc.description.affiliationDepartamento de Ginecologia e Obstetrícia Faculdade de Medicina de Botucatu Universidade Estadual Paulista Júlio de Mesquita Filho, Distrito de Rubião Júnior s/n, 18618-970 Botucatu, SP-
dc.description.affiliationUnespDepartment of Gynecology and Obstetrics Botucatu Medical School Sao Paulo State University, São Paulo-
dc.description.affiliationUnespDepartamento de Ginecologia e Obstetrícia Faculdade de Medicina de Botucatu Universidade Estadual Paulista Júlio de Mesquita Filho, Distrito de Rubião Júnior s/n, 18618-970 Botucatu, SP-
dc.identifier.doi10.1097/GME.0b013e318272bd4a-
dc.identifier.wosWOS:000316800700014-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofMenopause-
dc.identifier.scopus2-s2.0-84876187890-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.